Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cellectar Biosciences

0.2488
-0.0422-14.50%
Volume:1.74M
Turnover:432.90K
Market Cap:11.46M
PE:-0.18
High:0.2800
Open:0.2800
Low:0.2400
Close:0.2910
Loading ...

Cellectar Biosciences Inc - to Advance Clr 121225 and Clr 121125 Into Clinic

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Inc - to Pursue Strategic Options for Iopfosine I 131 Development

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences Inc - to Reduce Headcount by Approximately 60% by End of Q4 2024

THOMSON REUTERS
·
11 Dec 2024

Cellectar Biosciences trading halted, news pending

TIPRANKS
·
11 Dec 2024

Cellectar Biosciences transferred with Buy rating at Ladenburg

TIPRANKS
·
05 Dec 2024

BRIEF-Northstar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences For Therapeutic Radioisotope Actinium-225

Reuters
·
21 Nov 2024

Northstar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

THOMSON REUTERS
·
21 Nov 2024

Positive Buy Rating on Cellectar Biosciences Driven by Promising Iopofosine-131 Results and Strategic Advancements

TIPRANKS
·
21 Nov 2024

Cellectar Biosciences Is Maintained at Outperform by Oppenheimer

Dow Jones
·
19 Nov 2024

Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating

MT Newswires Live
·
19 Nov 2024

Cellectar Biosciences : Oppenheimer Cuts Target Price to $12 From $14

THOMSON REUTERS
·
19 Nov 2024

Cellectar Biosciences price target lowered to $12 from $14 at Oppenheimer

TIPRANKS
·
19 Nov 2024

Q3 2024 Cellectar Biosciences Inc Earnings Call

Thomson Reuters StreetEvents
·
19 Nov 2024

Cellectar Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
19 Nov 2024

Cellectar Biosciences reports Q3 EPS (40c), consensus (37c)

TIPRANKS
·
18 Nov 2024

Cellectar Biosciences sees cash runway into 2Q25

TIPRANKS
·
18 Nov 2024

Cellectar Biosciences' Q3 Cash And Cash Equivalents Of $34.3M Is Expected To Provide Cash Runway Into Q2 2025

Benzinga
·
18 Nov 2024

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

THOMSON REUTERS
·
18 Nov 2024

Cellectar Biosciences : Cash Balance as of Sept 30, to Fund Its Basic Budgeted Operations Into Q2 of 2025

THOMSON REUTERS
·
18 Nov 2024